Drug profile · INN
rilzabrutinib
WAYRILZ
rilzabrutinib (WAYRILZ) is a tyrosine-protein kinase btk inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — rilzabrutinib
- US status
- approved
- Class
- Nervous system (NOT)
- Route
- ORAL
- Patents
- 1
- Programs
- 11
- Data quality
- 0.84
Quick answer
rilzabrutinib (WAYRILZ) is a tyrosine-protein kinase btk inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase BTK inhibitor
Primary target: Tyrosine-protein kinase BTK
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is rilzabrutinib?
rilzabrutinib (WAYRILZ) is a tyrosine-protein kinase btk inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rilzabrutinib?
WAYRILZ is a marketed brand name for rilzabrutinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rilzabrutinib?
rilzabrutinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.